Результаты исследования препарата Хондроксид при остеоартрозе коленных суставов
Результаты исследования препарата Хондроксид при остеоартрозе коленных суставов
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Рациональная фармакотерапия ревматических заболеваний: руководство для практикующих врачей. Т. III. Гл. 12. М.: Литтерра, 2003.
2. Алексеева Л. И. Современные подходы к лечению остеоартроза. РМЖ. 2003; 11 (4): 201–5.
3. Osteoarthritis. Clinical and Experimental aspects. Ed. JE.Register, JP.Pelletier, Y.Pelletier. Henrotin. Springer, 1999.
4. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by: Koopman WJ, Moreland LW, Baltimore: Lippincott, William Wikins, 2005; 2199–96.
5. Felson DT, Laurence RC et al. Osteoarthritis: new insight. Part II: Treatment approach. Ann Intern Med 2000; 133: 726–37.
6. Laurence D, Massicotte F, Pelletier JP, Martel-Pelletier J. Subchondral bone sclerosis in osteoarthritis: not just an innocept bystander. Modem Rheumatol 2003; 13: 7–14.
7. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report or a Task Force of Stending Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
8. Zhang W, Moscovitz RW, Nuki G et al. OARSI recommendations for the menegement of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
9. Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflametory drug-associated upper gastrointestinal toxicity. Gastrointerol Clin N Am 2000; 29: 97–124.
10. Tenenbaum О. The epidemiology of nonsteroidal anti-inflametory drugs. Can J Gastrointerol 1999; 13: 119–22.
11. Насонова В.А., Алексеева Л.И., Архангельская Г.С. и др. Итоги многоцентрового клинического исследования препарата Структум в России. Тер. арх. 2001; 11: 84–7.
12. Насонов Е.Л., Алексеева Л.И. Хондроитин сульфат (Структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. Тер. арх. 2001; 11: 87–9.
13. Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984; 51: 1–11.
14. Jomphe C, Gabriac M, Hale TM et al. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear Factor-κB in Interleucin-1b-Stimulated Chondrocytes. Jornal complitation 2007 Nordic Pharmacological Sosiety & Clinical Pharmacology & Toxicology, 102: 59–65.
15. Hashimoto S, Takabasbi K, Amiel В et al. Chondrocyte apoptosis and nutric oxide production in expirementally induced osteoarthritis. Arthr Rheum 1998; 41: 1266–74.
16. Conrozier T. Death of articular chondrocytes. Mechanisms and protection. Pres Med 1998; 21: 1859–61.
17. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. LAMA 2000; 283: 1469–75.
18. Leeb BF, Schweizer M, Montag K, Smolen J. A meta-analisis of chondroitin sulphate in treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
19. Bana G, Jamard B, Verrouil E, Mazieres B. Chondroitin sulfate in the management of hip and knee OA: an overview. Adv Pharmacol 2006; 53: 507–22.
20. Michel BA, Stucki G, Frey D et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
21. Uebelhart D, Knols R, de Bruin ED, Verbruggen G. Chondroitin sulfate as a structure-modifying agent. Adv Pharmacol 2006; 53: 475–88.
22. Youyg Ho Lee, Jin-Hyun Woo et al. Effect of glucosamin or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int, Published on line: 21 June 2009.
23. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: SYDMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthrit Cartil 1998; 6 (Suppl. A): 37–8.
24. Jordan KMM, Arden NK. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Terapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
25. Hathcock JN, Shao A. Risk assessment for Glucosamine and chondroitin sulfate. Regulat Toxicol Pharmacol 2007; 47: 78–83.
2. Алексеева Л. И. Современные подходы к лечению остеоартроза. РМЖ. 2003; 11 (4): 201–5.
3. Osteoarthritis. Clinical and Experimental aspects. Ed. JE.Register, JP.Pelletier, Y.Pelletier. Henrotin. Springer, 1999.
4. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by: Koopman WJ, Moreland LW, Baltimore: Lippincott, William Wikins, 2005; 2199–96.
5. Felson DT, Laurence RC et al. Osteoarthritis: new insight. Part II: Treatment approach. Ann Intern Med 2000; 133: 726–37.
6. Laurence D, Massicotte F, Pelletier JP, Martel-Pelletier J. Subchondral bone sclerosis in osteoarthritis: not just an innocept bystander. Modem Rheumatol 2003; 13: 7–14.
7. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report or a Task Force of Stending Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
8. Zhang W, Moscovitz RW, Nuki G et al. OARSI recommendations for the menegement of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
9. Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflametory drug-associated upper gastrointestinal toxicity. Gastrointerol Clin N Am 2000; 29: 97–124.
10. Tenenbaum О. The epidemiology of nonsteroidal anti-inflametory drugs. Can J Gastrointerol 1999; 13: 119–22.
11. Насонова В.А., Алексеева Л.И., Архангельская Г.С. и др. Итоги многоцентрового клинического исследования препарата Структум в России. Тер. арх. 2001; 11: 84–7.
12. Насонов Е.Л., Алексеева Л.И. Хондроитин сульфат (Структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. Тер. арх. 2001; 11: 87–9.
13. Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984; 51: 1–11.
14. Jomphe C, Gabriac M, Hale TM et al. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear Factor-κB in Interleucin-1b-Stimulated Chondrocytes. Jornal complitation 2007 Nordic Pharmacological Sosiety & Clinical Pharmacology & Toxicology, 102: 59–65.
15. Hashimoto S, Takabasbi K, Amiel В et al. Chondrocyte apoptosis and nutric oxide production in expirementally induced osteoarthritis. Arthr Rheum 1998; 41: 1266–74.
16. Conrozier T. Death of articular chondrocytes. Mechanisms and protection. Pres Med 1998; 21: 1859–61.
17. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. LAMA 2000; 283: 1469–75.
18. Leeb BF, Schweizer M, Montag K, Smolen J. A meta-analisis of chondroitin sulphate in treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
19. Bana G, Jamard B, Verrouil E, Mazieres B. Chondroitin sulfate in the management of hip and knee OA: an overview. Adv Pharmacol 2006; 53: 507–22.
20. Michel BA, Stucki G, Frey D et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
21. Uebelhart D, Knols R, de Bruin ED, Verbruggen G. Chondroitin sulfate as a structure-modifying agent. Adv Pharmacol 2006; 53: 475–88.
22. Youyg Ho Lee, Jin-Hyun Woo et al. Effect of glucosamin or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int, Published on line: 21 June 2009.
23. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: SYDMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthrit Cartil 1998; 6 (Suppl. A): 37–8.
24. Jordan KMM, Arden NK. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Terapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
25. Hathcock JN, Shao A. Risk assessment for Glucosamine and chondroitin sulfate. Regulat Toxicol Pharmacol 2007; 47: 78–83.
Авторы
Е.П.Шарапова, Л.И.Алексеева
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.